As blockbuster acquisitions, asset swaps, and divestitures continue into 2016, we examine the key scientific, development, commercial, and business model issues facing an industry tasked with proving the value of its therapies like never before.
Hear from thought leaders across the spectrum of biotech, pharmaceutical, and payer perspectives as the drug industry embraces new strategies for long-term success.
Hear from thought leaders across the spectrum of biotech, pharmaceutical, and payer perspectives as the drug industry embraces new strategies for long-term success.
